Revance Therapeutics Inc (RVNC)

[DewDiligence]

2022 US sales of botulinum toxins for CD and spasticity were approximately $1.0B (slide #63 of the Investor Day slide set), so with expected growth the addressable market in 2024 should be $1.1-12.B.

Given Daxxify’s superior clinical data in CD, including the extended duration and ultralow rate of dysphagia, Daxxify ought to be able to capture 40%+ market share in CD and, say, 15% in (off-label) spasticity. So, we’re talking about roughly $250M annual revenue potential from these indications.